This US funded enterprise has clarified its confidence and direction for development in China through the CIIE
gb200
发表于 前天 11:10
3598
0
0
Shanghai, November 3 (Xinhua) - Boston Scientific, a US funded medical device company, recently announced two news in Shanghai. Firstly, its first production and manufacturing base in China has been built and opened in Lingang, Shanghai, which will serve the needs of local doctors and patients in China with a more agile and resilient supply chain; The second is to bring more than 80 cutting-edge medical technologies and products to participate in the 7th China International Import Expo, of which 5 will soon be launched in China through the CIIE platform.
It is reported that the Shanghai Lingang Base, as an important component of Boston Scientific's comprehensive localization strategy layout in China, will focus on the production of medical consumables and equipment with "leading technology and domestic intelligent manufacturing", covering the entire industry chain of trade, production, research and development, investment, and services. More than 80 cutting-edge medical technologies and products participated in the 7th CIIE, covering multiple fields such as heart, peripheral blood vessels, tumors, urology, digestion, and neural regulation that Boston Scientific excels in. Among them, the new generation intravascular ultrasound system is an innovative product with artificial intelligence characteristics. The Chinese R&D team has deeply participated in the related software and hardware research and development, and the core host is produced in China. It is not only the latest representative of Boston Scientific's local R&D and production, but also the "first release" in the Chinese market.
Zhang Jun, President of Boston Scientific Greater China, stated that the above two messages clearly demonstrate the confidence and direction of Boston Scientific's development in China, namely accelerating its transition from exhibitors to investors, increasing investment in the Chinese market, and growing together with the Chinese healthcare industry.
She said that this year marks the sixth consecutive year that Boston Science has participated in the CIIE. Every time we participate in the exhibition, we can strongly feel the enthusiasm and thirst of the Chinese market for cutting-edge medical innovation, and it is also a good opportunity for learning and exchange. "We have thus clarified what we should do in the Chinese market.
Statistics show that since its first participation in the CIIE in 2019, Boston Scientific has accumulated 21 innovative achievements that have transformed from exhibits to products, accelerating their listing in China. Since last year's CIIE alone, 9 innovative exhibits have been approved for listing in China. In sync with numerous innovative exhibits and accelerated technology launches, Boston Scientific's business in China has maintained double-digit growth in recent years.
Taking a hot steam therapy system for treating benign prostatic hyperplasia as an example, it was launched two and a half years earlier than the traditional pathway. In just one year, more than 5000 patients with benign prostatic hyperplasia in China have bid farewell to traditional gland resection surgery and received safer, more convenient, and efficient medical services. The acceleration and spillover effects of the CIIE are very obvious.
At the 7th CIIE, Boston Scientific will set up a neural regulation exhibition area for the first time, showcasing innovative medical solutions for managing chronic pain and treating Parkinson's disease. In the field of digestive health, Boston Scientific will focus on showcasing an innovative surgical treatment plan for adult obese individuals, which involves sleeve shaped shaping of the stomach under endoscopy, gradually reducing the volume of the stomach and achieving weight loss. This non-surgical surgery not only preserves the patient's organs but also has reversibility, providing more options for weight loss treatment.
Zhang Jun believes that it is the good effect of participating in the CIIE for years that has strengthened the confidence of Boston Scientific Headquarters in the Chinese market and made the decision to invest in the construction of the Shanghai Lingang Base. As a medical device company with a history of 45 years, Boston Scientific's judgment is that the Chinese market not only cannot be left, but also needs to increase investment.
Zhang Jun stated that the CIIE carries the grand vision of sharing China's opportunities with the world and promoting innovation between China and the world. As a permanent guest and beneficiary of the CIIE, Boston Scientific Future will share global innovation and management experience with Chinese partners in various aspects such as commercial licensing, R&D co creation, and compliance and systematic management empowerment through majority equity investment and strategic cooperation in China, promoting the extension of China's medical industry upstream of the global value chain and benefiting global patients with Chinese innovation.
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- The targeted therapy drug for chronic obstructive pulmonary disease, Dabitou, has been approved in China
- Sanofi: Targeted therapy drug for chronic obstructive pulmonary disease (COPD), Dabitou, approved in China
- General Motors Q3 sold over 420000 vehicles in China, surpassing gasoline powered vehicles for the first time in new energy vehicles
- Has the 'fixed price' policy been effective? General Motors' sales in China increased by 14.3% month on month in the third quarter, and SAIC GM's orders for certain models were overstocked
- Hyatt Hotels and China Resources Land establish a joint venture for light asset expansion, continuing to expand into the Chinese market
- The Boston Science Harbor Base has been completed and opened, achieving "independent production" in China
- When will Apple AI be launched in China? Cook responds!
- Beware of the US election triggering market volatility! BlackRock: This risk is underestimated
- Dialogue with Meng Pu, Chairman of Qualcomm China: Qualcomm has long-term accumulation in China and will adhere to the path of self-developed chips
- Pfizer's innovative targeted therapy drug Taizena has been approved in China
-
【英偉達の需要が高すぎる?SKハイニックス:黄仁勲がHBM 4チップの6カ月前納入を要求!】SKハイニックスの崔泰源(チェ・テウォン)会長は月曜日、インビダーの黄仁勲(ファン・インフン)CEOが同社の次世代高帯域 ...
- 琳271
- 昨天 17:54
- 支持
- 反对
- 回复
- 收藏
-
ファイザーが前立腺がんを治療する革新薬テゼナ& ;reg;(TALZENNA®,一般名:トルエンスルホン酸タラゾールパーリカプセル)は2024年10月29日に国家薬品監督管理局(NMPA)の承認を得て、HRR遺伝子突然変異 ...
- 什么大师特
- 1 小时前
- 支持
- 反对
- 回复
- 收藏
-
南方財経は11月5日、中央テレビのニュースによると、現地時間11月5日、米ボーイング社のストライキ労働者が59%の投票結果で新たな賃金協定を受け入れ、7週間にわたるストライキを終えた。ストライキ労働者は11月12 ...
- Dubssgshbsbdhd
- 3 小时前
- 支持
- 反对
- 回复
- 收藏
-
【マスクはテスラが携帯電話を作ることに応えた:作れるが作らないアップルとグーグルが悪さをしない限り】現地時間11月5日、有名ポッドキャストのジョローガン氏のインタビューに応じ、「携帯電話を作るのは私たち ...
- 波大老师
- 4 小时前
- 支持
- 反对
- 回复
- 收藏